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Background:  High  risk human  papillomavirus  (HR-HPV)  infection  is  common  and only  a  small  minority  of
infections  become  persistent  and  lead  to cervical  cancers.  Women  positive  for HR-HPV usually  require  a
second  test  to avoid  unnecessary  colposcopies  and  over  treatment.  Elevated  DNA  methylation  of HR-HPV
L1  and L2  genes  in high  grade  disease  has  emerged  as  a promising  molecular  triage  tool.
Objectives: Our  aim  was  to accurately  measure  methylation  levels  at selected  CpG  positions  in the  HPV18,
HPV31  and  HPV33  genomes.  We  focused  on  the  L2,  L1, URR and  E6  regions  because  these  were  previously
shown  to  be interesting  areas  for study.
Study design:  Pyrosequencing  was  used  to measure  methylation  in  208  HPV18,  207  HPV31,  and  126 HPV33
positive  women  selected  from  a London  colposcopy  referral  population.
Results: After  adjustment  for  multiple  testing,  at FDR  5%, elevated  methylation  was  signiﬁcantly  associatedyrosequencing with  cervical  intraepithelial  neoplasia  grades  2 or worse  (CIN2+)  in  all  investigated  CpGs  in HPV18  L2
and  L1.  Two  of  6  L2  and  12 of 15  L1  sites  in  HPV31  and  6 of  8 L2 and  3 of  13 L1 sites  in HPV33  showed
signiﬁcantly  elevated  methylation  in CIN2+.  Methylation  of CpG  sites  in  the  URR  and E6  region  of the
HPV  types  was  low  and most  differences  were  not  signiﬁcant.
Conclusion: Elevated  methylation  of  CpG  sites  in the  L1 and  L2  regions  of  HPV18,  HPV31 and  HPV33  is
associated  with  CIN2+  and  a panel  test  may  be useful  for triage  of  women  with  HR-HPV infections.
 201©
. Background
The main causative agent of cervical cancer is infection by
pproximately ﬁfteen high risk human papillomavirus types
HR-HPV) [1]. Although common, with an estimated worldwide
revalence of 11–12% [2], a majority of the infections clear within
 months to 2 years [3]. Consequently, a considerable number of
omen will acquire HR-HPV infection but very few will progress
Abbreviations: HR-HPV, high risk human papilloma virus; CIN, cervical intraep-
thelial neoplasia; CI, conﬁdence interval; FDR, false discovery rate; P1, predictors 1;
2, predictors 2; ROC, receiver operator characteristics; AUC, area under the curve;
CC, squamous cell carcinoma.     
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to invasive disease. The persisting infection fuels a decades long,
stepwise progression to cancer; recognition of which initiated the
use of cytological screening for the precursor cervical intraepithe-
lial neoplasia (CIN) as a common preventative practice [4]. In the
past decade, HR-HPV testing has been increasingly adapted as a
secondary triage tool in women 30 years or older [5,6]. Due to
its cost-effectiveness, approachability and high sensitivity, HR-HPV
testing is of interest as a primary preventative tool. However, cur-
rent HR-HPV tests cannot distinguish transient from persistent
infections, resulting in low speciﬁcity for detection of high grade
2 or 3 CIN lesions (CIN2/3). To compensate for the limitation,
different complementary methods have been suggested such as
cytology, p16 immunochemistry, genotyping and DNA methylation
[7]. While p16 immunochemistry and cytology rely on adequate
cellular material, PCR based techniques have fewer requirements
for preservation of the sample and can be applied to clinician or
self-collected specimens in liquid or dry form [8], making them
attractive for effective screening programme implementation in
Open access under CC BY-NC-SA license. less developed regions of the world.
Carefully orchestrated, DNA methylation plays a crucial role
for activating and silencing genes during normal development,
however its disruption contributes to development of disease [9].
cense. 
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PFig. 1. Consort diagram of the studied patients.
ntensive research in a variety of cancers shows great promise in
uantiﬁcation of DNA methylation as diagnostic and prognostic
iomarkers. In cervical cancer many studies have shown that ele-
ated methylation of CpG sites in the HPV16 L1 and L2 genes are
ssociated with CIN2/3 and cancers [10–14]. We recently reported
hat a classiﬁer score S1 developed in a study of Central American
omen based on HPV16 methylation of 7 CpG sites in L1 and L2
ad similar differentiating potential to identify CIN2/3 in HPV16
nfected European women, with 92% sensitivity and 40% speciﬁcity
13]. Methylation of other high risk types such as HPV18 [15–17]
nd HPV31 [17] have so far been investigated to a lesser extent than
PV16 and there are no methylation data on many HR-HPV types
uch as HPV33. Considering that HPV16 and 18 contribute to ∼70%
f cervical cancers [2,18] and that HPV31 and HPV33 are among
he next most prevalent HR-HPV types causing ∼8% of the can-
ers [19], we believe that extending methylation studies to these
R-HPV types may  lead to development of a more comprehensive
ethylation test for triage of women to colposcopy.
. Objective
The main aim of our study was to investigate DNA methylation
evels in different regions of the HPV18, HPV31 and HPV33 genomes
nd to test for associations between methylation and presence of
IN2+ in a London colposcopy referral population. A secondary aim
as to compare the methylation of HPV18, 31 and 33 in CIN2+ with
ingle versus multiple HR-HPV infection.
. Study design
We  followed the REMARK guidelines for evaluation of diagnostic
ests [20]. Methylation of 29 sites in HPV18, HPV31 and 27 sites in
PV33 (Supplemental Fig. 1) was measured by pyrosequencing in
08 HPV18, 207 HPV31 and 126 HPV33 positive patients.
.1. Population
Patients from two cohorts, Predictors 1 (P1) [21] and Predic-
ors 2 (P2) [22] were pooled to obtain a large number of HPV18,
PV31 and HPV33 positive samples (Fig. 1). The cohorts were
dentical in all parameters except the time of sample collection –
1 2005–2007 and P2 2007–2009. In summary, the two cohortsl Virology 59 (2014) 161–166
comprised 2052 women attending colposcopy at Hammersmith or
St Mary Hospital in London after a “mild dyskaryosis or worse”
cytology ﬁnding. Women  were eligible if they had been referred as a
result of one or more abnormal cervical smears, were not pregnant,
had not been treated previously for CIN, nor had a hysterectomy.
Prior to colposcopy, cervical specimens were obtained and stored in
PreservCyt transport medium. Initially, the samples were analysed
by a number of commercial HR-HPV test kits [21,22] and aliquots
stored in −70 ◦C until used for the current study. To identify HPV18,
HPV31 and HPV33 positive samples, Linear Array (Roche Molecu-
lar Systems, Inc., Pleasanton, CA, USA) data was used for P1 and BD
HPV test (BD Diagnostics, Burlington, NC, USA) for P2. In total, 208
HPV18, 207 HPV31 and 126 HPV33 positive patients were identi-
ﬁed. All analyses are based on a centrally reviewed histopathology
and take the highest grade of abnormality seen in the biopsy or
treatment specimen within 9 months of the initial base-line visit as
the ﬁnal diagnosis. If no abnormal areas were visible at colposcopy,
biopsy was not taken and these women were classiﬁed in the <CIN2
group.
All women  received a patient information sheet explaining the
study and provided written consent. Approvals were obtained from
the relevant local research ethics committee.
3.2. DNA isolation and bisulﬁte conversion
300 l of PreservCyt was  centrifuged at 13,200 rpm for 2 min
and the pellet was resuspended in 200 l PBS. The genomic DNA
was extracted with QIAamp DNA Mini Kit (Qiagen Inc., Hilden,
Germany) following the spin protocol recommended by the man-
ufacturer except that DNA was eluted in 60 l AE buffer. 250 ng
of DNA was used in the bisulﬁte conversion reactions where
unmethylated cytosines were converted to uracil with the EZ DNA
methylation kit (Zymo research, Irvine, CA) according to manufac-
turer’s instructions.
3.3. The methylation assays
Primers for 8 PCRs in L2, L1, URR and E6 covering 29 CpG pos-
itions in HPV18 (Supplemental Table 1), 7 PCRs in L2, L1 and URR
covering 29 CpG positions in HPV31 (Supplemental Table 2) and 7
PCRs in L2, L1 and URR covering 27 CpG positions in HPV33 (Sup-
plemental Table 3) were obtained using PyroMark Assay Design
software version 2.0.1.15 (Qiagen). All CpGs within L2, L1 and URR
were mapped (Supplemental Fig. 1) and the primers were designed
with intent to cover the densest CpG areas in a single amplicon
of less than 300 bp. CpG positions in 3′ end of HPV18 E6 gene
were investigated as a surrogate for the 5′ end of URR for which
we could not obtain a functional assay. Overlapping of CG dyads
was avoided to prevent ampliﬁcation biases. To provide the inter-
nal control for total bisulﬁte conversion, a non-CpG cytosine in the
region for pyrosequencing was  included where possible. PCRs were
performed using a converted DNA equivalent of 1600 cells employ-
ing the PyroMark PCR kit (Qiagen) assuming 6.6 pg DNA per diploid
cell for calculations. Brieﬂy, 12.5 l PCR master mix, 2.5 l Coral
red, 1 l primer-mix, 2 l DNA and optimised amount of MgCl2
were adjusted with water to give a ﬁnal 25 l reaction. The ﬁnal
concentration of each primer for HPV31 and HPV33 assays was
0.2 M,  while the concentration differed for HPV18 assays (Sup-
plemental Table 1). All the assays were run with thermal cycling
conditions: 95 ◦C for 15 min, optimised number of cycles: 30 s at
94 ◦C; 30 s at the optimised annealing temperature; 30 s at 72 ◦C
and a ﬁnal extension varied between 5 and 10 min  at 72 ◦C (Sup-
plemental Tables 1–3). In each run, a non-template negative control
was run in addition to a standard curve consisting of 1 pg/ml
of 0, 50 and 100% methylated HPV plasmid in a background of
10 ng/ml human DNA. The ampliﬁed DNA was conﬁrmed on QIAxel
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Fig. 2. (A) The median methylation presented for each of the investigated CpG pos-
itions in HPV18. The methylation was overall higher in CIN2+ (black bar) comparing
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Fig. 3. (A) The median methylation presented for each of the investigated CpG pos-
itions in HPV31. The methylation was overall higher in CIN2+ (black bar) comparing
ence between the two diagnostic groups, this site had an AUC of
0.59 [95CI 0.53–0.66] p = 0.0037. High correlation was  observed
between methylation of CpG positions within the genes (Fig. 2b).o  <CIN2 (white bar) in the capsid coding genes. The p-values (*) were plotted on the
ight Y-axis and the 5% FDR is marked by a dashed line. (B) The heat map showing
pearman r correlation between all investigated sites.
apillary electrophoresis instrument (Qiagen). 10 l of PCR product
as pyrosequenced using a PyroMarkTMQ96 ID (Qiagen) instru-
ent as previously described [23].
.4. Statistical analyses
The non-parametric Wilcoxon test was used to determine
hether the proportion of methylation at each individual CpG site
as associated with HPV infection outcome. Heatmaps were con-
tructed according to Spearman rho correlation values for each CpG
ite. To account for the high number of CpG positions tested on
he same data, the Benjamin and Hochberg step-up procedure for
ontrolling false discovery rate (FDR) was applied with FDR of 5%
24]. The classiﬁcation ability of each CpG position was  evaluated by
eceiver operating characteristics (ROCs), area under the ROC curve
AUC). For the analysis of methylation in CIN2+ with multiple infec-
ions, the 15 types considered as HR-HPV were 16, 18, 31, 33, 35,
9, 45, 51, 52, 56, 58, 59, 68, 73, 82 [1]. STATA v12 and GraphPad
rism v5.03 were used for statistical analysis and illustrations.
. Results
.1. Methylation of HPV18
The methylation of 29 sites was measured in 208 HPV18 posi-
ive patients. Three patients were excluded from the analysis – 2
atients failed to amplify for all assays and 1 patient had unspeciﬁed
istology. The CIN2+ group consisted of 74 CIN2/3, 1 invasive squa-
ous cell carcinoma (SCC) and one adenocarcinoma. 129 patients
ad diagnosis <CIN2. The median age in all HPV18 positive samples
as 29 years with interquartile range (IQR) 6. Per diagnostic group,
edian age was 28 in CIN2+ and 29 in <CIN2. Age was not corre-ated to the methylation of any sites as the Spearman rho ranged
rom −0.08 to 0.18.
Overall median methylation measured higher in the CIN2+ in
2 and L1 genes (Fig. 2). All interrogated sites in HPV18 L2 andto  <CIN2 (white bar) in the capsid coding genes. The p-values (*) were plotted on
the  right Y-axis and the FDR 5% is shown. (B) The heat map  showing Spearman r
correlation between all investigated sites. Negative correlations are marked by (−).
L1 sites were signiﬁcantly higher in CIN2+ after adjustment for
multiple comparisons. Low methylation was observed in URR and
E6 CpG sites with only site 7316 showing a signiﬁcant differ-Fig. 4. (A) The median methylation presented for each of the investigated CpG pos-
itions in HPV33. The methylation was higher in CIN2+ (black bar) comparing to
<CIN2 (white bar) in 6 L2 and 3 L1 sites. The p-values (*) were plotted on the right
Y-axis and the FDR 5% is shown. (B) The heat map  showing Spearman’s r correlation
between all investigated sites. Negative correlations are marked by (−).
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Fig. 5. Median methylation of (a) HPV18, (b) HPV31 and (c) HPV33 L2 and L1 in CIN2+ group in single infections (white bar) vs. multiple infections (black bar). A patient was
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Tonsidered to have multiple infection if positive for any of the 15 HR-HPV types. Ou
ere  37 single and 62 multiple infections. HPV33 infected CIN2+ consisted of 21 sin
he AUC and p-values for each site in L1 and L2 are presented in
upplemental Table 4.
.2. Methylation of HPV31
The methylation of 29 sites was measured in 207 HPV31 positive
atients. One patient was excluded due to an unspeciﬁed histol-
gy. In the case group, 99 patients were diagnosed with CIN2/3
nd none with cancer. 107 patients comprised the control group
<CIN2). The median age was 28 years in each group as well as
n all HPV31 positive women with interquartile range (IQR) 6.
ge was not correlated to the methylation of HPV31 sites with
pearman rho ranging from −0.10 to 0.13. Median methylation
n the investigated sites in HPV31 L2 and L1 measured higher in
IN2+ compared to <CIN2 (Fig. 3a). Two of 6 L2 and 12 of 15 L1
ites showed signiﬁcantly higher methylation after adjustment for
ultiple comparisons. Highest correlation was observed between
he sites within the L1 and L2 gene (Fig. 3b). The AUC and p-
alues for each site in L1 and L2 is presented in Supplemental
able 5. HPV18 positive CIN2+, 14 were single infections and 63 multiple. For HPV31, there
d 53 multiple infections. Unadjusted p-values (*) were plotted on the right Y-axis.
4.3. Methylation of HPV33
The methylation of 27 sites was  measured in 126 HPV33 positive
patients. Nine patients (2 cases and 7 controls) failed to amplify
with all assays and were therefore excluded from the analysis. Out
of remaining 117 patients, there were 74 cases (72 CIN2/3 and 2
SCC) and 43 controls (<CIN2). Median age was 29 each group, and
28 in all analysed samples with interquartile range (IQR) 4. Age was
not correlated to the methylation of HPV33 sites as the Spearman
rho ranged from −0.06 to 0.10.
Median methylation measured higher in the CIN2+ group in 6
out of 8 sites in L2 and 3 out of 13 sites investigated in HPV33
L1 (Fig. 4a). The AUC and p-values for each site in L1 and L2 is pre-
sented in Supplemental Table 6. The correlation of methylation was
highest within L2 CpG sites and L1 CpG sites (Fig. 4b).
4.4. Methylation in single vs. multiple infectionsMethylation was compared between single and multiple infec-
tions in CIN2+ (Fig. 5). A multiple infection was deﬁned as CIN2+
infected with at least two of the 15 HR-HPV types. For HPV18,
linica
m
i
w
i
H
L
p
5
a
(
w
F
g
1
p
E
a
t
a
m
t
s
i
v
o
u
i
0
a
a
H
m
i
f
a
m
i
r
q
b
a
r
H
g
t
t
C
i
H
y
m
i
d
i
o
f
s
g
sN. Vasiljevic´ et al. / Journal of C
edian methylation was signiﬁcantly higher in single infections
n all L2 sites and 11 of 14 L1 sites (Fig. 5a). Median methylation
as signiﬁcantly higher in HPV31 L1 sites 6984 and 7008 in single
nfections and in L2 site 5522 in multiple infections (Fig. 5b). For
PV33, although methylation appeared higher in several sites in
2 and 6986 in L1, none were signiﬁcant at  ˛ = 0.05 (Fig. 5c). The
-values in Fig. 5 were not corrected for multiple testing.
. Discussion
The methylation of many CpG sites in L2 of HPV18, HPV31
nd HPV33 were signiﬁcantly higher in CIN2+ compared to <CIN2
Figs. 2–4) while the methylation of CpGs in the URR and E6 gene
ere overall low and did not differ between the diagnostic groups.
or the L1 gene, methylation was signiﬁcantly higher in all investi-
ated sites in HPV18, a majority of HPV31 sites and in only 3 out of
3 sites in HPV33. This may  reﬂect that we had the smallest group of
atients positive for HPV33, warranting a larger study with HPV33.
levated methylation in CpG positions in capsid genes of HPV18
nd HPV31 is in line with previous reports [15–17] and conﬁrm
hat assessment of methylation in these HPV types may  be a good
pproach for development of an effective triage tool to comple-
ent HPV16, which has been previously validated as a promising
riage biomarker [13]. The highest AUC reached was 0.69 for HPV18
ites 6363, 6366 and 7090 (Supplemental Table 4) and site 6951
n HPV31 (Supplemental Table 5). A previous study reported AUC
alues for the corresponding sites of approximately 0.8 [17]. This
bserved difference may  be due to differences in the populations
nder study as ours was a colposcopy referral group and also we
ncluded CIN1 in the control group. For HPV33, the highest AUC of
.70 was reached for site 6986 in spite of the smaller patient group
nd presence of CIN1 in the control group. We  report a signiﬁcant
nd fair separation by at least one site for each of the investigated
PV CpGs and suggest that an expansion of S1 classiﬁer [13] to
ethylation of additional HPV is warranted and likely to increase
ts effectiveness.
A limitation of our study is that we used archived specimens
rom a set of women referred to colposcopy due to one or more
bnormal cytology tests. Although this allowed us to investigate
ethylation in a large group of CIN2+, our results need to be val-
dated in women who were identiﬁed as HR-HPV positive during
outine screening in the general population. Furthermore, pyrose-
uencing is a highly efﬁcient and accurate quantiﬁcation method
ut is limited to relatively short reads. Our study did not include an
ssessment of all CpG sites in each HPV types; however, a previous
eport has shown high correlation between CpG sites within the
PV18 and 31 genes [17] and therefore we believe that we  investi-
ated a sufﬁcient number of sites to allow the development of new
riage classiﬁers for HPV18, HPV31 and HPV33.
Interestingly, similarly to previous ﬁndings [17], the methyla-
ion of HPV18 and HPV31 capsid genes appeared to be higher in
IN2+ with a single infection (Fig. 5), the mechanism behind which
s unknown at the present time. A plausible explanation is that the
PV type driving the carcinogenesis is subjected to more meth-
lation as a cellular defence. In specimens that contain DNAs of
ultiple HPVs it is often not clear which HPV type is the driver;
f methylation pressure is actually exerted preferentially on the
river it may  allow a differentiation between driver and passenger
nfections.
In summary, we conﬁrm that methylation of the capsid genes
f HPV18 and HPV31 is elevated in high grade disease. We  report
or the ﬁrst time the methylation of 27 sites in L2 and L1 HPV33
howing that 8 sites in L2 and 3 sites in L1 were elevated in high
rade disease. A next step is development of a comprehensive clas-
iﬁer where methylation of HR-HPV types 16, 18, 31, 33 and 45 isl Virology 59 (2014) 161–166 165
combined to identify high grade disease. We  believe that an
expanded classiﬁer may  serve as an effective triage tool for HR-HPV
positive women  and improve cervical cancer prevention.
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